Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Intravacc and SynphaBase Conjugate Vaccine Partnership | Lucid Diligence Brief
Can Intravacc and SynphaBase create a streamlined synthetic glycan-to-GMP…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…
Lucid Diligence Brief: kyron.bio x Servier strategic partnership
Lucid Diligence Brief: kyron.bio x Servier strategic partnership Professional…
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC Professional…
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide licensing agreement
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide…
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…